Switching to a New Schistosomiasis Treatment
Author Information
Author(s): Meyer Thorsten, Sekljic Harald, Fuchs Stefan, Bothe Heiko, Schollmeyer Dieter, Miculka Christian
Primary Institution: Intervet Innovation GmbH
Hypothesis
The non-schistosomicidal component in praziquantel contributes to its unpleasant taste.
Conclusion
Using the pure schistosomicidal component of praziquantel could reduce the required dose and improve patient compliance due to a better taste.
Supporting Evidence
- The schistosomicidal component alone is significantly less bitter than regular, racemic praziquantel.
- Thirteen out of fifteen panel members found (R)-PZQ to taste less bitter than racemic PZQ.
- The study confirmed that the unpleasant taste of praziquantel is mainly due to the non-active component.
Takeaway
The study found that a new version of a medicine for a disease called schistosomiasis tastes better than the old one, which could help kids take their medicine more easily.
Methodology
The study involved separating praziquantel into its components and conducting a taste test with a panel of adults.
Potential Biases
The panel members were untrained in sensory testing, which may affect the results.
Limitations
The taste test panel consisted only of adults, not children, who are the target demographic for the treatment.
Participant Demographics
The taste test panel consisted of 15 adult members.
Statistical Information
P-Value
0.0107
Statistical Significance
p=0.0018
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website